Analyst consensus rating
Apnimed Analyst Rating: Strong Buy
APMD is rated Strong Buy by 2 analysts with a $50.50 target. As of 2026-08-29.
Direct answer
Apnimed's consensus rating is Strong Buy.
2 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $50.50.
Forecast evidence checked August 29, 2026.
Get free Apnimed email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $29.71
- Average price target
- $50.50
- High price target
- $60.00
- Low price target
- $41.00
- Low target gap
- +38%
- Target upside
- +70%
- High target gap
- +102%
- Target range width
- 64%
- Consensus rating
- Strong Buy
- Analysts
- 2
- Evidence date
- August 29, 2026
- Valid through
- September 5, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Apnimed?
Apnimed has a verified Strong Buy consensus. The same dataset has an average price target of $50.50.
How far are Apnimed's low and high targets from the recorded price?
The low target implies +38%, while the high target implies +102%.
How many analysts are included in Apnimed's consensus?
The verified consensus includes 2 analysts.
How is Apnimed's target upside or downside calculated?
The average target of $50.50 is divided by the recorded price of $29.71, then one is subtracted to produce +70%. This does not guarantee a future return.
When was Apnimed's analyst forecast verified?
The data was verified on 2026-08-29. The dataset is valid through 2026-09-05.